# Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant

> **NCT02464878** · PHASE2 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 2 (actual)

## Conditions studied

- Kidney Transplant
- Type 1 Diabetes

## Interventions

- **DRUG:** Alpha 1-Antitrypsin
- **PROCEDURE:** Islet Transplantation
- **DRUG:** Thymoglobulin
- **DRUG:** Basiliximab
- **DRUG:** Etanercept

## Key facts

- **NCT ID:** NCT02464878
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01
- **Primary completion:** 2022-11
- **Final completion:** 2022-12
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2023-12-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02464878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02464878, "Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02464878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*